Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13000 participants
INTERVENTIONAL
2014-01-01
2016-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The overall aim of this research is to examine the impact of differing invitation letters offered to participants on study recruitment rates.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Cardiovascular Health, Nutrition and Physical Functioning in Older Adults in Spain
NCT03541135
Evaluating Quebec's Red-Cross Intervention
NCT05099042
Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke
NCT03928509
Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens
NCT04699851
Cardiovascular Risk Prevention Among Night Workers
NCT02899442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The research described here will examine the impact of differing invitation letters offered to participants on study recruitment rates, with the following specific objectives:
* Understanding if the gender of the person signing the invitation letter has an effect on recruitment
* Exploring the potential impact of the use of describing the research as a 'study' or as a 'project'
* Understanding if discussing and guaranteeing confidentiality for the participants in the invitation letter has an impact on recruitment.
We will do this by randomly allocating each of the 13000 participants contacted by NICOLA to receive invitation letter by one of the following three choices using a 3x2x2 factorial design:
1. Gender of the signatory (male versus female versus neutral team signature)
2. Description of NICOLA (study versus project)
3. Guarantee of confidentiality (inserted versus removed)
We will then analyse the numbers of participants agreeing to join NICOLA and use this to determine which invitation letter is the most acceptable to the participants. This research will occur within the first 18 months of NICOLA, when all participants are being recruited.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Potential NICOLA Participants
All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
Invitation letter randomisation
There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:
1. Male \& Study \& Confidentiality
2. Male \& Study
3. Male \& Project \& Confidentiality
4. Male \& Project
5. Female \& Project \& Confidentiality
6. Female \& Project
7. Female \& Study \& Confidentiality
8. Female \& Study
9. Neutral \& Study \& Confidentiality
10. Neutral \& Study
11. Neutral \& Project \& Confidentiality
12. Neutral \& Project
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Invitation letter randomisation
There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:
1. Male \& Study \& Confidentiality
2. Male \& Study
3. Male \& Project \& Confidentiality
4. Male \& Project
5. Female \& Project \& Confidentiality
6. Female \& Project
7. Female \& Study \& Confidentiality
8. Female \& Study
9. Neutral \& Study \& Confidentiality
10. Neutral \& Study
11. Neutral \& Project \& Confidentiality
12. Neutral \& Project
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must be living in an non-institutionalised environment.
* Participants must be capable of providing informed consent.
Exclusion Criteria
* Participants who are institutionalised.
* Participants who are not capable of providing informed consent.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen's University, Belfast
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lisa Maguire
Research Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mike Clarke, PhD
Role: PRINCIPAL_INVESTIGATOR
Queen's University, Belfast
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lisa Maguire
Belfast, Northern Ireland, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.